PAI
MNTA

Palo Alto Investors’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Palo Alto Investors’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,479,524
Closed -$49.2M – 45
2020
Q2 		$49.2M Sell
1,479,524
-48,432
-3% -$1.54M 2.96% 13
2020
Q1 		$41.6M Sell
1,527,956
-157,416
-9% -$4.38M 3.48% 14
2019
Q4 		$33.3M Sell
1,685,372
-71,750
-4% -$1.15M 1.83% 19
2019
Q3 		$22.8M Sell
1,757,122
-162,191
-8% -$1.96M 1.52% 19
2019
Q2 		$23.9M Buy
1,919,313
+77,700
+4% +$1.03M 1.16% 20
2019
Q1 		$26.8M Hold
1,841,613
– – 1.12% 21
2018
Q4 		$20.3M Buy
1,841,613
+8,081
+0.4% +$112K 1.08% 21
2018
Q3 		$48.2M Hold
1,833,532
– – 1.95% 17
2018
Q2 		$37.5M Buy
1,833,532
+3,097
+0.2% +$66.5K 1.5% 17
2018
Q1 		$33.2M Buy
1,830,435
+8,859
+0.5% +$148K 1.42% 21
2017
Q4 		$25.4M Buy
1,821,576
+26,578
+1% +$359K 1.09% 21
2017
Q3 		$33.2M Buy
1,794,998
+7,422
+0.4% +$124K 1.4% 20
2017
Q2 		$30.2M Buy
1,787,576
+28,200
+2% +$429K 1.41% 19
2017
Q1 		$23.5M Buy
1,759,376
+31,996
+2% +$501K 1.11% 22
2016
Q4 		$26M Buy
1,727,380
+76,504
+5% +$1.01M 1.48% 20
2016
Q3 		$19.3M Buy
1,650,876
+21,800
+1% +$256K 1.12% 23
2016
Q2 		$17.6M Buy
1,629,076
+160,300
+11% +$1.65M 1.33% 22
2016
Q1 		$13.6M Hold
1,468,776
– – 1.05% 24
2015
Q4 		$21.8M Buy
1,468,776
+13,600
+0.9% +$228K 1.21% 19
2015
Q3 		$23.9M Hold
1,455,176
– – 1.15% 18
2015
Q2 		$33.2M Hold
1,455,176
– – 1.48% 16
2015
Q1 		$22.1M Hold
1,455,176
– – 1.09% 22
2014
Q4 		$17.5M Hold
1,455,176
– – 1.03% 21
2014
Q3 		$16.5M Hold
1,455,176
– – 1.23% 18
2014
Q2 		$17.6M Buy
1,455,176
+140,200
+11% +$1.66M 1.31% 21
2014
Q1 		$15.3M Buy
1,314,976
+157,700
+14% +$2.67M 1.27% 20
2013
Q4 		$20.5M Buy
1,157,276
+20,600
+2% +$346K 1.91% 16
2013
Q3 		$16.4M Sell
1,136,676
-38,400
-3% -$588K 1.71% 17
2013
Q2 		$17.7M Buy
+1,175,076
New +$15.5M 2.09% 15

Other funds holding MNTA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Palo Alto Investors's MNTA Position: Q3 2020 in Review

Palo Alto Investors sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q3 2020, closing a stake of 1,479,524 shares — an estimated $49.2M sold.

Palo Alto Investors first reported a position in MNTA in Q2 2013 and held it in 29 quarters. The position peaked at $49.2M in Q2 2020. 211 funds tracked by Wall St. Rank hold MNTA as of Q3 2020.

  • Palo Alto Investors reported no remaining Momenta Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Palo Alto Investors sold 1,479,524 Momenta Pharmaceuticals, Inc. shares in Q3 2020, an estimated $49.2M.
  • Palo Alto Investors first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
  • Palo Alto Investors's Momenta Pharmaceuticals, Inc. position peaked at $49.2M in Q2 2020.
  • 211 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2020.

Based on Palo Alto Investors's 13F filing for Q3 2020, filed 16 Nov 2020.